Skip to main content
Top
Published in: Nutrition Journal 1/2015

Open Access 01-12-2015 | Research

Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus

Authors: Raynold V Yin, Olivia J Phung

Published in: Nutrition Journal | Issue 1/2015

Login to get access

Abstract

Aims

Chromium (Cr) is a trace element involved in glucose homeostasis. We aim to evaluate and quantify the effects of Cr supplementation on A1C and FPG in patients with T2DM.

Materials and methods

A systematic literature search of Pubmed, EMBASE and the Cochrane Library (from database inception to 11/2014) with no language restrictions sought RCTs or cohort studies evaluating Cr supplementation in T2DM vs control and reporting either change in glycated hemoglobin (A1C) or fasting plasma glucose (FPG). Meta-analysis was conducted on each subtype of Cr supplement separately, and was analyzed by random effects model to yield the weighted mean differences (WMD) and 95% confidence intervals (CIs). Heterogeneity was assessed by using the I2 statistic.

Results

A total of 14 RCTs (n = 875 participants, mean age range: 30 to 83 years old, 8 to 24 weeks of follow-up) were identified (Cr chloride: n = 3 study, Cr picolinate: n = 5 study, brewer’s yeast: n = 4 study and Cr yeast: n = 3 study). Compared with placebo, Cr yeast, brewer’s yeast and Cr picolinate did not show statistically significant effects on A1C. Furthermore, compared to control, Cr chloride, Cr yeast and Cr picolinate showed no effect on FPG, however, brewer’s yeast showed a statistically significant decrease in FPG -19.23 mg/dL (95% CI = -35.30 to -3.16, I2 = 21%, n = 137).

Conclusions

Cr supplementation with brewer’s yeast may provide marginal benefits in lowering FPG in patients with T2DM compared to placebo however it did not have any effect on A1C.
Literature
1.
go back to reference Yeghiazaryan K, Schild HH, Golubnitschaja O: Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics.Infect Disord Drug Targets 2012,12(5):332–9. 10.2174/187152612804142215CrossRefPubMedPubMedCentral Yeghiazaryan K, Schild HH, Golubnitschaja O: Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics.Infect Disord Drug Targets 2012,12(5):332–9. 10.2174/187152612804142215CrossRefPubMedPubMedCentral
2.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.Diabetes Care 2004, 27:1047–53. 10.2337/diacare.27.5.1047CrossRefPubMed Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.Diabetes Care 2004, 27:1047–53. 10.2337/diacare.27.5.1047CrossRefPubMed
3.
go back to reference Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, Dobre D, Denig P: A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients.Health Qual Life Outcomes 2011, 9:83. doi:10.1186/1477–7525–9-83 10.1186/1477-7525-9-83CrossRefPubMedPubMedCentral Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, Dobre D, Denig P: A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients.Health Qual Life Outcomes 2011, 9:83. doi:10.1186/1477–7525–9-83 10.1186/1477-7525-9-83CrossRefPubMedPubMedCentral
4.
go back to reference Yeh GY, Eisenberg DM, Davis RB, Phillips RS: Use of complementary and alternative medicine among persons with diabetes mellitus: results of a national survey.Am J Public Health 2002,92(10):48–52.CrossRef Yeh GY, Eisenberg DM, Davis RB, Phillips RS: Use of complementary and alternative medicine among persons with diabetes mellitus: results of a national survey.Am J Public Health 2002,92(10):48–52.CrossRef
5.
go back to reference Egede LE, Ye X, Zheng D, Silverstein MD: The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes.Diabetes Care 2002,25(2):324–9. 10.2337/diacare.25.2.324CrossRefPubMed Egede LE, Ye X, Zheng D, Silverstein MD: The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes.Diabetes Care 2002,25(2):324–9. 10.2337/diacare.25.2.324CrossRefPubMed
6.
go back to reference Nutrition Business Journal: NBJ’s Supplement Business Report 2003. San Diego, CA: Penton Media Inc; 2003. Nutrition Business Journal: NBJ’s Supplement Business Report 2003. San Diego, CA: Penton Media Inc; 2003.
7.
go back to reference Rabinovitz H, Friedensohn A, Leibovitz A, Gabay G, Rocas C, Habot B: Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients.Int J Vitam Nutr Res 2004,74(3):178–82. 10.1024/0300-9831.74.3.178CrossRefPubMed Rabinovitz H, Friedensohn A, Leibovitz A, Gabay G, Rocas C, Habot B: Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients.Int J Vitam Nutr Res 2004,74(3):178–82. 10.1024/0300-9831.74.3.178CrossRefPubMed
9.
go back to reference Vincent JB: Elucidating a biological role for chromium at a molecular level.Acc Chem Res 2000,33(7):503–10. 10.1021/ar990073rCrossRefPubMed Vincent JB: Elucidating a biological role for chromium at a molecular level.Acc Chem Res 2000,33(7):503–10. 10.1021/ar990073rCrossRefPubMed
10.
go back to reference Lee NA, Reasner CA: Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM.Diabetes Care 1994,17(12):1449–52. 10.2337/diacare.17.12.1449CrossRefPubMed Lee NA, Reasner CA: Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM.Diabetes Care 1994,17(12):1449–52. 10.2337/diacare.17.12.1449CrossRefPubMed
11.
go back to reference DerSimonian R, Laird N: Meta-analysis in clinical trials.Control Clin Trials 1986,7(3):177–88. 10.1016/0197-2456(86)90046-2CrossRefPubMed DerSimonian R, Laird N: Meta-analysis in clinical trials.Control Clin Trials 1986,7(3):177–88. 10.1016/0197-2456(86)90046-2CrossRefPubMed
12.
go back to reference Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al.: Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ 2011, 343:d5928. 10.1136/bmj.d5928CrossRefPubMedPubMedCentral Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al.: Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ 2011, 343:d5928. 10.1136/bmj.d5928CrossRefPubMedPubMedCentral
13.
go back to reference Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test.BMJ 1997,315(7109):629–34. 10.1136/bmj.315.7109.629CrossRefPubMedPubMedCentral Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test.BMJ 1997,315(7109):629–34. 10.1136/bmj.315.7109.629CrossRefPubMedPubMedCentral
14.
go back to reference Wallach S: Clinical and biochemical aspects of chromium deficiency.J Am College Nutr. 1985, 4:107–20. 10.1080/07315724.1985.10720070CrossRef Wallach S: Clinical and biochemical aspects of chromium deficiency.J Am College Nutr. 1985, 4:107–20. 10.1080/07315724.1985.10720070CrossRef
15.
go back to reference Sharma S, Agrawal RP, Choudhary M, Jain S, Goyal S, Agarwal V: Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes.J Trace Elem Med Biol 2011,25(3):149–53. doi:10.1016/j.jtemb.2011.03.003. Epub 2011 May 12 10.1016/j.jtemb.2011.03.003CrossRefPubMed Sharma S, Agrawal RP, Choudhary M, Jain S, Goyal S, Agarwal V: Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes.J Trace Elem Med Biol 2011,25(3):149–53. doi:10.1016/j.jtemb.2011.03.003. Epub 2011 May 12 10.1016/j.jtemb.2011.03.003CrossRefPubMed
16.
go back to reference Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, et al.: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.Diabetes 1997,46(11):1786–91. 10.2337/diab.46.11.1786CrossRefPubMed Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, et al.: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.Diabetes 1997,46(11):1786–91. 10.2337/diab.46.11.1786CrossRefPubMed
17.
go back to reference Abraham AS, Brooks BA, Eylath U: The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes.Metabolism 1992,41(7):768–71. 10.1016/0026-0495(92)90318-5CrossRefPubMed Abraham AS, Brooks BA, Eylath U: The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes.Metabolism 1992,41(7):768–71. 10.1016/0026-0495(92)90318-5CrossRefPubMed
18.
go back to reference Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA: The effects of inorganic chromium and brewer’s yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes.Saudi Med J 2000,21(9):831–7.PubMed Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA: The effects of inorganic chromium and brewer’s yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes.Saudi Med J 2000,21(9):831–7.PubMed
19.
go back to reference Bahijri SM, Mufti AM: Beneficial effects of chromium in people with type 2 diabetes, and urinary chromium response to glucose load as a possible indicator of status.Biol Trace Elem Res 2002,85(2):97–109. 10.1385/BTER:85:2:097CrossRefPubMed Bahijri SM, Mufti AM: Beneficial effects of chromium in people with type 2 diabetes, and urinary chromium response to glucose load as a possible indicator of status.Biol Trace Elem Res 2002,85(2):97–109. 10.1385/BTER:85:2:097CrossRefPubMed
20.
go back to reference Chen YL, Lin JD, Hsia TL, Mao FC, Hsu CH, Pei D: The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes.Eur J Nutr 2014,53(1):127–33. 10.1007/s00394-013-0508-8CrossRefPubMed Chen YL, Lin JD, Hsia TL, Mao FC, Hsu CH, Pei D: The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes.Eur J Nutr 2014,53(1):127–33. 10.1007/s00394-013-0508-8CrossRefPubMed
21.
go back to reference Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, et al.: Role of chromium supplementation in Indians with type 2 diabetes mellitus.J Nutr Biochem 2002,13(11):690–7. 10.1016/S0955-2863(02)00220-6CrossRefPubMed Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, et al.: Role of chromium supplementation in Indians with type 2 diabetes mellitus.J Nutr Biochem 2002,13(11):690–7. 10.1016/S0955-2863(02)00220-6CrossRefPubMed
22.
go back to reference Hunt AE, Allen KGD, Smith BA: Effect of chromium supplementation on hair chromium concentration and diabetic status.Nutr Res 1985,5(2):131–40. 10.1016/S0271-5317(85)80028-2CrossRef Hunt AE, Allen KGD, Smith BA: Effect of chromium supplementation on hair chromium concentration and diabetic status.Nutr Res 1985,5(2):131–40. 10.1016/S0271-5317(85)80028-2CrossRef
23.
go back to reference Jain SK, Kahlon G, Morehead L, Dhawan R, Lieblong B, Stapleton T, et al.: Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-α, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study.Mol Nutr Food Res 2012,56(8):1333–41. doi:10.1002/mnfr.201100719. Epub 2012 Jun 6 10.1002/mnfr.201100719CrossRefPubMedPubMedCentral Jain SK, Kahlon G, Morehead L, Dhawan R, Lieblong B, Stapleton T, et al.: Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-α, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study.Mol Nutr Food Res 2012,56(8):1333–41. doi:10.1002/mnfr.201100719. Epub 2012 Jun 6 10.1002/mnfr.201100719CrossRefPubMedPubMedCentral
24.
go back to reference Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, Meyboom-de Jong B, et al.: Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial.Diabetes Care 2006,29(3):521–5. 10.2337/diacare.29.03.06.dc05-1453CrossRefPubMed Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, Meyboom-de Jong B, et al.: Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial.Diabetes Care 2006,29(3):521–5. 10.2337/diacare.29.03.06.dc05-1453CrossRefPubMed
25.
go back to reference Król E, Krejpcio Z, Byks H, Bogdański P, Pupek-Musialik D: Effects of chromium brewer’s yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients.Biol Trace Elem Res 2011,143(2):726–37. doi:10.1007/s12011–010–8917–5. Epub 2010 Dec 18 10.1007/s12011-010-8917-5CrossRefPubMed Król E, Krejpcio Z, Byks H, Bogdański P, Pupek-Musialik D: Effects of chromium brewer’s yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients.Biol Trace Elem Res 2011,143(2):726–37. doi:10.1007/s12011–010–8917–5. Epub 2010 Dec 18 10.1007/s12011-010-8917-5CrossRefPubMed
26.
go back to reference Lai MH: Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and e supplementation for type 2 diabetes mellitus.J Clin Biochem Nutr 2008,43(3):191–8. doi:10.3164/jcbn.2008064. Epub 2008 Oct 31 10.3164/jcbn.2008064CrossRefPubMedPubMedCentral Lai MH: Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and e supplementation for type 2 diabetes mellitus.J Clin Biochem Nutr 2008,43(3):191–8. doi:10.3164/jcbn.2008064. Epub 2008 Oct 31 10.3164/jcbn.2008064CrossRefPubMedPubMedCentral
27.
go back to reference Racek J, Trefil L, Rajdl D, Mudrová V, Hunter D, Senft V: Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus.Biol Trace Elem Res 2006,109(3):215–30. 10.1385/BTER:109:3:215CrossRefPubMed Racek J, Trefil L, Rajdl D, Mudrová V, Hunter D, Senft V: Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus.Biol Trace Elem Res 2006,109(3):215–30. 10.1385/BTER:109:3:215CrossRefPubMed
28.
go back to reference Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B: Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus.Am Heart J 2005,149(4):632–6. 10.1016/j.ahj.2004.07.021CrossRefPubMed Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B: Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus.Am Heart J 2005,149(4):632–6. 10.1016/j.ahj.2004.07.021CrossRefPubMed
29.
go back to reference Kleefstra N, Houweling ST, Bakker SJ, Verhoeven S, Gans RO, Meyboom-de Jong B, et al.: Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial.Diabetes Care 2007,30(5):1092–6. Epub 2007 Feb 15 10.2337/dc06-2192CrossRefPubMed Kleefstra N, Houweling ST, Bakker SJ, Verhoeven S, Gans RO, Meyboom-de Jong B, et al.: Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial.Diabetes Care 2007,30(5):1092–6. Epub 2007 Feb 15 10.2337/dc06-2192CrossRefPubMed
30.
go back to reference Schwarz K, Mertz W: Chromium(III) and the glucose tolerance factor.Arch Biochem Biophys. 1959, 85:292–5. 10.1016/0003-9861(59)90479-5CrossRefPubMed Schwarz K, Mertz W: Chromium(III) and the glucose tolerance factor.Arch Biochem Biophys. 1959, 85:292–5. 10.1016/0003-9861(59)90479-5CrossRefPubMed
Metadata
Title
Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus
Authors
Raynold V Yin
Olivia J Phung
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Nutrition Journal / Issue 1/2015
Electronic ISSN: 1475-2891
DOI
https://doi.org/10.1186/1475-2891-14-14

Other articles of this Issue 1/2015

Nutrition Journal 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine